AIRLINK 74.40 Decreased By ▼ -0.76 (-1.01%)
BOP 5.39 Decreased By ▼ -0.06 (-1.1%)
CNERGY 4.37 Decreased By ▼ -0.02 (-0.46%)
DFML 29.20 Increased By ▲ 1.56 (5.64%)
DGKC 77.14 Increased By ▲ 5.14 (7.14%)
FCCL 20.85 Increased By ▲ 0.56 (2.76%)
FFBL 30.89 Decreased By ▼ -0.16 (-0.52%)
FFL 10.20 Increased By ▲ 0.23 (2.31%)
GGL 10.65 Increased By ▲ 0.38 (3.7%)
HBL 114.60 Decreased By ▼ -0.40 (-0.35%)
HUBC 131.38 Decreased By ▼ -0.07 (-0.05%)
HUMNL 6.80 Decreased By ▼ -0.07 (-1.02%)
KEL 4.08 Decreased By ▼ -0.12 (-2.86%)
KOSM 4.74 Decreased By ▼ -0.03 (-0.63%)
MLCF 39.78 Increased By ▲ 2.70 (7.28%)
OGDC 134.90 Decreased By ▼ -0.55 (-0.41%)
PAEL 24.53 Increased By ▲ 1.13 (4.83%)
PIAA 27.65 Increased By ▲ 0.34 (1.24%)
PIBTL 6.70 Increased By ▲ 0.10 (1.52%)
PPL 114.00 Increased By ▲ 0.84 (0.74%)
PRL 28.70 Decreased By ▼ -0.05 (-0.17%)
PTC 15.29 Decreased By ▼ -0.21 (-1.35%)
SEARL 57.40 Increased By ▲ 0.07 (0.12%)
SNGP 66.75 Decreased By ▼ -0.24 (-0.36%)
SSGC 11.14 Decreased By ▼ -0.03 (-0.27%)
TELE 9.19 Increased By ▲ 0.05 (0.55%)
TPLP 12.07 Increased By ▲ 0.02 (0.17%)
TRG 70.46 Increased By ▲ 0.07 (0.1%)
UNITY 24.00 Increased By ▲ 0.35 (1.48%)
WTL 1.33 Decreased By ▼ -0.01 (-0.75%)
BR100 7,477 Increased By 21.7 (0.29%)
BR30 24,373 Increased By 123.4 (0.51%)
KSE100 71,650 Increased By 216.4 (0.3%)
KSE30 23,637 Increased By 70.6 (0.3%)
World

Merkel says Sputnik V needs EMA approval before discussing joint production

  • Merkel said Germany's vaccines regulator, the Paul Ehrlich Institute, could offer Russia guidance on EMA's approval process for Sputnik V.
Published January 21, 2021

BERLIN: A discussion about joint production of Russia's COVID-19 vaccine Sputnik V can happen if the vaccine is approved by the European Medical Agency (EMA), German Chancellor Angela Merkel said on Thursday.

Merkel said Germany's vaccines regulator, the Paul Ehrlich Institute, could offer Russia guidance on EMA's approval process for Sputnik V.

Russia's sovereign wealth fund has filed for registration of Sputnik V in the European Union and expects it to be reviewed in February, the official account promoting the COVID-19 vaccine tweeted on Wednesday.

Comments

Comments are closed.